Navigation Links
Due to Generic Erosion, the Hypertension Drug Market Will Decline by $3 Billion from 2009 to 2019

BURLINGTON, Mass., Sept. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, owing to increasing generic availability of antihypertensive agents, the hypertension drug market will decline from $26 billion in 2009 to $23 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Hypertension reveal that the market-leading drug, Novartis's Diovan/Tareg, will suffer the greatest decline as its sales will decrease more than $1 billion in 2013, following the entry of generic versions of the drug. By 2019, the drug classes typically used as first-, second-, and third-line therapy will all be subject to generic competition — these drug classes are the angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (AIIRA), calcium channel blockers (CCBs) and diuretics.

"Emerging agents will find it difficult to penetrate the highly genericized hypertension market because of competition from inexpensive and efficacious generic antihypertensive drugs," said Decision Resources Analyst Taskin Ahmed. "Through 2019, we do not forecast blockbuster sales for any of the emerging antihypertensive agents."

The Pharmacor 2010 findings also reveal that, although the overall market will decline, sales of therapies offering greater convenience, such as fixed-dose combinations, will increase over the next several years. The CCB/ renin-angiotensin-aldosterone system (RAAS) inhibitor fixed-dose combinations and CCB/RAAS inhibitor/diuretic fixed-dose combinations will capitalize on this opportunity, generating approximately $6 billion in total sales in 2019.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Generic Drug Sector Gets Better Information on API Manufacturing Costs from Thomson Reuters and Rondaxe Enterprises
2. Thomson Reuters Explores the Opportunities and Challenges of Entering the Japanese Generic Drug Market
3. Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents
4. Forty-two of Simceres Generic Drugs Enter Chinas Essential Drug List
5. GPhA Says BIO Cries Wolf on Senate Biogenerics Proposal
6. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets
7. Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
8. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
9. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
11. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
Post Your Comments:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... Program that includes over 2,000 technical presentations offered in symposia, oral sessions, ... and applied spectroscopy, covers a wide range of applications such as, but not ...
(Date:11/26/2015)... November 26, 2015 ... Accutest Research Laboratories, a leading ... Organization (CRO), has formed a strategic ... - Temple Health for joint work ... (Photo: ) , --> ...
(Date:11/25/2015)... , November 26, 2015 ... Global Biobanking Market 2016 - 2020 report analyzes ... maintaining integrity and quality in long-term samples, minimizing ... long-term cost-effectiveness. Automation minimizes manual errors such as ... technical efficiency. Further, it plays a vital role ...
(Date:11/25/2015)... 2 nouvelles études permettent d , identifier ... souches bactériennes retrouvées dans la plaque dentaire des ... Ces recherches  ouvrent une nouvelle voie ... l,un des problèmes de santé les plus fréquemm ... --> 2 nouvelles études permettent d , ...
Breaking Biology Technology:
(Date:11/18/2015)... Nov. 18, 2015  As new scientific discoveries deepen ... and other healthcare providers face challenges in better using ... patients. In addition, as more children continue to survive ... adulthood and old age. John M. Maris, ... Hospital of Philadelphia (CHOP) . --> ...
(Date:11/17/2015)... PARIS , November 17, 2015 ... November 2015.   --> Paris from ... --> DERMALOG, the biometrics innovation leader, has invented the ... and fingerprints on the same scanning surface. Until now two ... fingerprints. Now one scanner can capture both on the same ...
(Date:11/17/2015)... 17, 2015  Vigilant Solutions announces today that Mr. ... of Directors. --> --> ... from the partnership at TPG Capital, one of the ... $140 Billion in revenue.  He founded and led TPG,s ... TPG companies, from 1997 to 2013.  In his first ...
Breaking Biology News(10 mins):